Old and new stomach therapy with bismuth salts. Pharmacokinetics, pharmacodynamics, toxicity
Börsch, G.
Medizinische Klinik 83(18): 605-610
1988
ISSN/ISBN: 0723-5003 PMID: 3054463 Document Number: 317318
Document emailed within 1 workday
Related Documents
Henry, J.; Luciani, L. 1986: Octanol-water partition coefficient of different bismuth salts Annales Pharmaceutiques Francaises 44(6): 443-447Lechat, P.; Palliere, M.; Gernez, G.; Dechy, H.; Letteron, N. 1976: Comparative disposition of bismuth in the rat after repeated oral administration of different salts Annales Pharmaceutiques Francaises 34(5-6): 179-182
Molina, J.A.; Calandre, L.; Bermejo, F.; Posadas, F.; Fernández-Ortega, J.D. 1989: Myoclonic encephalopathy caused by bismuth salts. Efficacy of treatment with dimercaprol Medicina Clinica 93(1): 20-22
Anderson, J.E.; Morris, R.E.; Blaschke, T.F. 1987: Pharmacodynamics of cyclosporine-ketoconazole interaction in mice. Combined therapy potentiates cyclosporine immunosuppression and toxicity Transplantation 43(4): 529-533
Buge, A.; Rancurel, G.; Poisson, M.; Dechy, H. 1974: Myoclonic encephalopathies induced by bismuth salts. 6 cases observed during long-term oral treatment La Nouvelle Presse Medicale 3(36): 2315-2320
Krari, N.; Mauras, Y.; Allain 1995: Enhancement of bismuth toxicity by l-cysteine Research Communications in Molecular Pathology and Pharmacology 89(3): 357-364
Chen, J.T.; Kurokawa, Y.; Nakayama, K.; Saito, K.; Sakamoto, K.; Fukuda, K.; Hirai, Y.; Hamada, T.; Fujimoto, I.; Yamauchi, K. 1987: The effect of bismuth subnitrate on cisplatin toxicity Nihon Sanka Fujinka Gakkai Zasshi 39(5): 815-822
Scharf, S.; Christophidis, N. 1993: Relevance of pharmacokinetics and pharmacodynamics Medical Journal of Australia 158(6): 395-402
Nordt, T.K.; Moser, M.; Kohler, B.; Kübler, W.; Bode, C. 1999: Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA) Thrombosis and Haemostasis 82 Suppl. 1: 121-123
Nikolaidis, P.P. 1993: Quinolones: pharmacokinetics and pharmacodynamics Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 13(Suppl 2): S377-S379
Mizikov, V.M.; Lovtsevich, N.V.; Rudenko, M.V.; Vereshchagina, I.I. 1999: Remifentanyl: pharmacokinetics, pharmacodynamics, use Anesteziologiia i Reanimatologiia 6: 19-22
Morikawa, T.; Kawamura, E. 1989: A method of cisplatin administration with the aid of high-dose bismuth subnitrate, and their pharmacokinetics Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(4 Pt: 2-1): 1094-1098
Crom, W.R. 1992: Effect of chirality on pharmacokinetics and pharmacodynamics American Journal of Hospital Pharmacy 49(9 Suppl 1: S9-14
Gehr, T.W.; Sica, D.A.; Brater, D.C.; Wallace, H.J.; Davis, J.; Fakhry, I. 1991: Metolazone pharmacokinetics and pharmacodynamics in renal transplantation International Journal of Clinical Pharmacology Therapy and Toxicology 29(3): 116-123
Suttle, A.B.; Songer, S.S.; Dukes, G.E.; Hak, L.J.; Koruda, M.; Fleishaker, J.C.; Brouwer, K.L. 1992: Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics Journal of Clinical Psychopharmacology 12(4): 282-287
Hansen, C.P. 2003: The pharmacokinetics and pharmacodynamics of progastrin-derived peptides Danish Medical Bulletin 50(4): 310-319
Zbinden, G. 1972: Morphological aspects of pharmacokinetics and pharmacodynamics (report) Verhandlungen der Deutschen Gesellschaft für Pathologie 56: 29-33
Liu, M.J.; Brouwer, K.L.; Pollack, G.M. 1992: Pharmacokinetics and pharmacodynamics of valproate analogs in rats. III. Pharmacokinetics of valproic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid in the bile-exteriorized rat Drug Metabolism and Disposition: the Biological Fate of Chemicals 20(6): 810-815
Golden, R.N.; Gilmore, J.H.; Carson, S.W. 1991: Antidepressant challenge tests: the interface of pharmacokinetics and pharmacodynamics Psychopharmacology Bulletin 27(4): 611-617
Dutta, S.; Ebling, W.F. 1998: Formulation-dependent pharmacokinetics and pharmacodynamics of propofol in rats Journal of Pharmacy and Pharmacology 50(1): 37-42